I will admit not reading the JAMA report from cover to cover, much of it would be Greek to me anyway. What I don't believe has been covered to date in any depth is the status of the survivors. All who're still surviving are now over 7 or 8 years, I'm not certain, from entering the trial, some may have survived over 15 years. The question is, are these people still fighting the disease, or deemed to be in complete remission, but monitored, or considered cured and no longer undergoing anything more than an annual physical. I don't know if such information could be presented at SNO, but if not I hope it will be presented at some time.
Years ago, as I remember it, the company had several long term survivors in their appearance in the Experts Theater at ASCO. Now that we've got the Journal, I believe the company will announce the Annual Meeting shortly. If they wished to do a presentation including patients it would make for a very different Annual Meeting, but that is unlikely. What I believe they could do, and others do somewhat routinely, is host a Science Day, an opportunity for investors to hear from the scientists, and I believe patients could be included in such a presentation. The Science Day doesn't take a full day, normally it's an hour or two, Analysts and some investors may be permitted to ask questions, though most are logged into a webcast where they can just look and listen. I think it would be money well spent in sponsoring such a webcast.
Gary
Market Data 
Markets 
AI
